Endocyte Inc (NASDAQ:ECYT)
| 14.23 Data as of May 21 |  +0.07 / +0.49%Today’s Change | 6.01 Today|||52-Week Range 15.36 | +58.46% Year-to-Date |
Latest ECYT News | Press Releases
No recent news for Endocyte Inc.
Today’s Trading
| Previous close | 14.16 |
| Today’s open | 14.17 |
| Day’s range | 14.00 - 14.42 |
| Volume | 159,648 |
| Average volume (3 months) | 290,107 |
| Market cap | $509.4M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/21/2013
Growth & Valuation
| Earnings growth (last year) | +65.71% |
| Earnings growth (this year) | +9.03% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +18,055.99% |
| P/E ratio | NM |
| Price/Sales | 9.28 |
| Price/Book | 5.11 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| MACKMerrimack Pharmaceut... | -0.01 | -0.19% |
| SNTASynta Pharmaceutical... | +0.08 | +1.08% |
| CMRXChimerix Inc | +0.11 | +0.55% |
| EBSEmergent BioSolution... | -0.13 | -0.91% |
Data as of 4:03pm ET, 05/21/2013
Financials
| Next reporting date | August 15, 2013 |
| EPS forecast (this quarter) | -$0.09 |
| Annual revenue (last year) | $34.7M |
| Annual profit (last year) | -$17.3M |
| Net profit margin | -49.86% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director P. Ron Ellis, MBA |
Chief Financial Officer Michael A. Sherman, MBA |
Corporate headquarters West Lafayette, Indiana |
Forecasts
